Dietary Oncopharmacognosy as a Crosswalk between Precision Oncology and Precision Nutrition

Abstract

While diet and nutrition are modifiable risk factors for many chronic and infectious diseases, their role in cancer prevention and control remains under investigation. The lack of clarity of some diet–cancer relationships reflects the ongoing debate about the relative contribution of genetic factors, environmental exposures, and replicative errors in stem cell division as determinate drivers of cancer risk. In addition, dietary guidance has often been based upon research assuming that the effects of diet and nutrition on carcinogenesis would be uniform across populations and for various tumor types arising in a specific organ, i.e., that one size fits all. Herein, we present a paradigm for investigating precision dietary patterns that leverages the approaches that led to successful small-molecule inhibitors in cancer treatment, namely understanding the pharmacokinetics and pharmacodynamics of small molecules for targeting carcinogenic mechanisms. We challenge the scientific community to refine the paradigm presented and to conduct proof-in-concept experiments that integrate existing knowledge (drug development, natural products, and the food metabolome) with developments in artificial intelligence to design and then test dietary patterns predicted to elicit drug-like effects on target tissues for cancer prevention and control. We refer to this precision approach as dietary oncopharmacognosy and envision it as the crosswalk between the currently defined fields of precision oncology and precision nutrition with the goal of reducing cancer deaths.

Rethinking the Role of Orexin in the Regulation of REM Sleep and Appetite

“…After all, recent studies suggest the use of drugs that act on orexinergic receptors also in the treatment of different cancers including colon, pancreas and prostate cancers [54] and neurodegenerative diseases [55,56] such as Alzheimer's disease (AD) where orexinergic system dysregulation promotes sleep-wake cycle impairment [57] and also interacts with CSF AD biomarkers, such as beta-amyloid and tau proteins. Along this line, the role of nutrition in sleep medicine [58] and secondary prevention strategies is continuously increasing both in oncology and neurodegeneration [59,60].…”